| cholestyramine vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Venous thromboembolism | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | stroke (fatal and non fatal) | no data | | Coronary event | 0.83 [0.66 1.03] | p=1.00 | 0 | 3806 | 1 | LRC, | | Coronary death and non fatal MI | no data | | Coronary death | 0.79 [0.51 1.25] | p=1.00 | 0 | 3949 | 2 | NHLBI (Brensike),LRC, | | cardiac death | no data | | MACE | no data | | Non fatal MI | 0.82 [0.64 1.04] | p=1.00 | 0 | 3806 | 1 | LRC, | | All cause death | 0.94 [0.68 1.30] | p=1.00 | 0 | 3949 | 2 | NHLBI (Brensike),LRC, | | non cardiovascular death | 1.12 [0.70 1.78] | p=1.00 | 0 | 3949 | 2 | NHLBI (Brensike),LRC, | | Fatal stroke | no data | | Haemmorhagic stroke | no data | | new-onset diabetes | no data | | Death from cancer | 1.06 [0.52 2.16] | p=1.00 | 0 | 3806 | 1 | LRC, | | Rhabdomyolysis | no data | | Myopathy | no data | | Cancer | no data | | Adverse events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
